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2-C-Methyl-D-erythritol 4-phosphate synthase (IspC) is
the first enzyme committed to isoprenoid biosynthesis
in the methylerythritol phosphate pathway, which rep-
resents an alternative route to the classical mevalonate
pathway. As it is present in many pathogens and plants,
but not in man, this pathway has attracted considerable
interest as a target for novel antibiotics and herbicides.
Fosmidomycin represents a specific high-affinity inhib-
itor of IspC. Very recently, its anti-malaria activity in
man has been demonstrated in clinical trials. Here, we
present the crystal structure of Escherichia coli IspC in
complex with manganese and fosmidomycin at 2.5 Å
resolution. The (N-formyl-N-hydroxy)amino group pro-
vides two oxygen ligands to manganese that is present
in a distorted octahedral coordination, whereas the
phosphonate group is anchored in a specific pocket by
numerous hydrogen bonds. Both sites are connected by
a spacer of three methylene groups. The substrate mol-
ecule, 1-D-deoxyxylulose 5-phosphate, can be superim-
posed onto fosmidomycin, explaining the stereochemi-
cal course of the reaction.
Malaria represents one of the most threatening diseases
especially in developing countries with about 300 million cases
every year, resulting in more than one million deaths per year
(1). Although it had been believed that malaria will be eradi-
cated shortly, the present experience is to the contrary because
the disease is escalating even in countries with satisfactory
medical services. This and the development of multi-resistant
variants of other pathogenic organisms define the urgent need
for novel chemotypes of antibiotics that expand the repertoire
of the presently targeted biochemical pathways (2, 3). The
availability of the genome sequence of Plasmodium falciparum,
the causative agent of malaria, and especially the wealth of
information on the biochemical pathways used by this orga-
nism have opened novel approaches for drug development (4,
5). Specifically, the mevalonate-independent “2-C-methyl-D-
erythritol 4-phosphate (MEP)1 pathway” (Fig. 1a), which leads
to the universal isoprenoid precursors isopentenyl diphosphate
(IPP) (Fig. 1a, 4) and dimethylallyl diphosphate (DMAPP) (Fig.
1a, 5) via 2-C-methyl-D-erythritol 4-phosphate (Fig. 1a, 2) and
(E)-1-hydroxy-2-methyl-but-2-enyl 4-diphosphate (Fig. 1a, 3)
has attracted considerable interest (6, 7). The existence of this
pathway in certain eubacteria and plants has been demon-
strated by pioneering studies of Rohmer et al. (8) and Arigoni
and co-workers (9, 10) (reviewed in Refs. 11–13). Evidence has
been accumulated for its presence in many pathogenic micro-
organisms including the malaria parasite Plasmodium spp.
that harbor the MEP pathway in their apicoplast compart-
ments (14). As the pathway is not present in man where IPP
and DMAPP are exclusively synthesized via mevalonate (Fig.
1a, 6), all enzymes of the 2-C-methyl-D-erythritol 4-phosphate
(MEP) pathway represent promising targets for the develop-
ment of novel drugs.
The first compound unique to the mevalonate-independent
MEP pathway (Fig. 1a, 2) is synthesized from 1-D-deoxyxylu-
lose 5-phosphate (Fig. 1a, 1) by IspC (15) via intramolecular
rearrangement of 1-D-deoxyxylulose 5-phosphate (Fig. 1a, 1)
(10, 16–18) followed by NADPH-dependent reduction of the
aldehyde intermediate, 2-C-methyl-D-erythrose 4-phosphate
(Fig. 1b, 8). The aldehyde intermediate can be chemically syn-
thesized and converted either into the substrate, 1-D-deoxyxy-
lulose 5-phosphate, or the product, 2-C-methyl-D-erythritol
4-phosphate, by IspC and nicotinamide nucleotides depending
on the reaction conditions, which demonstrates not only full
reversibility of the reaction but also that 2-C-methyl-D-ery-
throse 4-phosphate is a true intermediate (19). The stereo-
chemical course of the reaction has been studied by isotope-
labeling experiments and analysis of the resulting compounds
by NMR spectroscopy both in vivo (20) and in vitro (21, 22). The
enzymatic properties of IspC from Escherichia coli have been
studied in detail (19, 23, 24). The enzymes from E. coli,
Chlamydomonas, Arabidopsis thaliana, and P. falciparum, are
susceptible to inhibition by fosmidomycin (Fig. 1c, 9) (6, 23, 25,* The costs of publication of this article were defrayed in part by the
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26). Thus, fosmidomycin and its derivative, FR-900098 (Fig. 1c,
10), have also been shown to cure mice infected by
Plasmodium vinckei (6). Clinical trials showed that fosmido-
mycin can be used with a high rate of success for the treatment
of malaria (7).
The three-dimensional structure of the E. coli enzyme with-
out ligands and with NADPH and phosphate has been deter-
mined (27, 28). However, no structural information on sub-
strate or inhibitor complexes is available. Here, we present the
crystal structure of E. coli IspC in complex with the nanomolar
inhibitor fosmidomycin at 2.5 Å resolution and discuss its im-
plication for the reaction mechanism and the design of drugs.
FIG. 1. a, methylerythritol phosphate and mevalonate pathway of isoprenoid biosynthesis. IPP (4) and DMAPP (5) are either synthesized from
acetyl-CoA (7) via mevalonate (6) or from 1-deoxy-D-xylulose 5-phosphate (1) via 2-C-methyl-D-erythritol 4-phosphate (2) and (E)-1-hydroxy-2-
methyl-but-2-enyl 4-diphosphate (3). b, stereochemical course of the reaction performed by IspC. 1-deoxy-D-xylulose 5-phosphate (1) is converted
into 2-C-methyl-D-erythritol 4-phosphate (4) via the aldose intermediate 2-C-methyl-D-erythrose 4-phosphate (8) that is reduced by NADPH after
isomerization. Route A for a fomidomycin-like binding of the intermediate 8 leads to the incorrect stereochemistry, whereas route B results in the
correct stereochemistry. The migrating group (C-4) and the hydride from NADPH attack on opposite sites of C-2 and C-3, respectively. The asterisk
indicates the hydride transferred from NADPH. c, chemical structures of the IspC inhibitors fosmidomycin (9) and FR-900098 (10).
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MATERIALS AND METHODS
Expression, Purification, and Crystallization—The ispC gene of
E. coli was cloned and overexpressed, and the corresponding gene
product was purified as described previously (29). For crystallization,
the protein was dialyzed against 100 mM Tris/HCl, pH 8.0, with 2 mM
dithioerythritol and 0.02% (m/v) NaN3 and concentrated to 10 mg/ml.
15 l of the protein solution were mixed with 15 l of the buffer solution
containing 8% (w/v) polyethylene glycol (PEG) 4000 and 100 mM sodium
acetate, 110 mM Hepes, 100 mM glycine, 100 mM guanidinium chloride,
10 mM EDTA, 12 mM dithiothreitol, pH 5.8, and equilibrated over 900 l
of the same buffer without EDTA in Linbro plates at 21 °C. The protein
had a strong tendency to precipitate irreversibly. Diffraction quality
crystals appeared rather irregularly after about 1 week and grew to a
final size of about 0.45  0.2  0.2 mm3.
Structure Solution and Refinement—Data sets of the substrate-free
crystals and the complexes were measured at 100 K using an Oxford
cryo stream. Prior to flash freezing or soaking, the crystals were grad-
ually transferred in about ten steps into a buffer solution containing the
mother liquor without EDTA supplemented with 30% (v/v) polyethylene
glycol 400 during a time period of about 30 min. For soaking, either 5
mM MnCl2 (data set MN) or 5 mM MnCl2 together with 2 mM fosmido-
mycin (data set MNFOS) were added to the cryo solution. Crystals were
soaked for 2 h. Fosmidomycin was purchased from Molecular Probes
(Eugene, Oregon).
X-ray diffraction data were collected on a MarResearch imaging plate
detector mounted on a Rigaku rotating anode x-ray generator operating
at 50 kV and 100 mA. Diffraction data were evaluated with the HKL
suite (30) and CCP4 program suite (31). The crystal structure of the apo
E. coli IspC (Protein Data Bank entry 1K5H) (27) of space group C222
(1) with three monomers in the asymmetric unit provided the starting
set of coordinates. Model building was done with the program MAIN
(32). The structures were refined with CNS (33) using a test set of 5%
of the reflections for cross-validation. Starting R-factors after Patterson
search with MOLREP (31) and rigid body refinement with crystallog-
raphy NMR software were in the range of 43–47%. Models were refined
by iterative rounds of model building, simulated annealing, least
squares, and B-factor refinement. Finally, water molecules were picked
with crystallography NMR software or manually. Non-crystallographic
symmetry restraints were applied throughout the refinement. Initially
the maximum likelihood target using amplitudes was applied, but in
the final round the residual target was used because it was found to
result in lower Rfree values. The structures display good stereochemical
parameters as estimated by the program PROCHECK (34). The Ram-
achandran plot (35) showed only 0.0% (apo), 1.3% (MN) or 0.8% (MN-
FOS) in the generously allowed region and 0.3% (apo) and 0.0% (MN
and MNFOS) in the disallowed regions. Figures were prepared with
BOBSCRIPT (36). The coordinates have been deposited with the Pro-
tein Data Bank under accession codes 1ONN, 1ONO, and 1ONP.
RESULTS AND DISCUSSION
Structure Solution—Recombinant 2-C-methyl-D-erythritol
4-phosphate synthase (EC 1.1.1.267) of E. coli has been crys-
tallized in a monoclinic crystal form of space group P2(1) that is
unrelated to that previously described (27, 28). The asymmetric
unit contains a dimer that also represents the solution state of
the enzyme (Fig. 2). The crystals showed unisotropic diffraction
of x-ray to between 2.8 and 2.3 Å resolution and a rather high
mosaicity of about 1°. Based on the merging R-factor of the
data and I/(I) criteria for the outermost shell, useful data were
included to a limiting resolution of 2.6 Å for the apo data set
and 2.5 Å for the complex data sets with Mn2 (MN) and
Mn2/fosmidomycin (MNFOS), respectively (Table I). The
known crystal structure of E. coli IspC (27) provided the start-
ing model for the Patterson search. The resulting models were
refined with non-crystallographic symmetry restraints until
the crystallographic R-factors converged (Table I). The rela-
tively high final Rwork and Rfree can be explained by the uniso-
tropic diffraction and the high mosaicity. Nevertheless, the
electron density was of high quality, and the Mn2/fosmidomy-
cin moieties were excellently defined by simulated annealing
omit maps (Fig. 3). Inclusion of non-crystallographic symmetry
improved refinement behavior significantly, which indicates
that both monomers are also rather similar with respect to
their domain arrangement.
The model for the apo form contains residues 1–397 exclud-
ing the active site loop, which is completely disordered (resi-
dues Arg-208 to Gly-215). In the presence of Mn2/fosmidomy-
cin, significant additional electron density is present for this
loop that can be fitted as shown in Fig. 4. However, it appears
that the catalytic loop remains partially disordered, especially
for Ser-213 and Met-214, which are not defined by electron
density, and it very likely adopts more than one conformation.
Interestingly, Met-214 represents a strictly conserved residue.
This can be explained if it is assumed that complete ordering of
the catalytic loop requires the presence of both NADPH and the
substrate 1-D-deoxyxylulose 5-phosphate.
Overall Structure—IspC forms an elongated homodimer of
about 96  60 Å with a pronounced cleft-like structure in each
monomer that is covered by a flexible active site loop (Fig. 2).
Each monomer can be subdivided into basically three domains.
The N-terminal domain (residues 1–149) is a member of the
FIG. 2. Ribbon diagram of the IspC
dimer viewed along the dimer axis.
Each monomer can be divided into three
domains. The N-terminal domain (red)
binds NADPH (light green ball-and-stick
model) and represents a classical dinucle-
otide binding fold. The central catalytic
domain (yellow) binds the divalent metal
(magnesium, manganese, or cobalt) and
the substrate. Fosmidomycin is depicted
as orange ball-and-stick model. It also
harbors the flexible active site loop (ma-
genta). A connecting stretch (blue) leads
to a C-terminal -helical domain that
supports the catalytic domain.
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classical dinucleotide binding fold and serves as an anchor for
NADPH. A central catalytic domain (residues 150 to 285) har-
bors both the binding site for the divalent metal ion (Mg2,
Mn2, or Co2), the phosphate binding site of the substrate,
and the catalytic loop. The C-terminal all--helical domain
(residues 312 to 398) is connected to the catalytic domain by a
linker region that spans the entire monomer. The C-terminal
domain appears to have a structural role in supporting the
catalytic domain. The catalytic domain can even be subdivided
into the part harboring the substrate binding site and that
harboring the active site loop.
Binding of Manganese and Fosmidomycin and Implications
for Anti-malaria Drug Development—IspC was crystallized in
the absence of divalent metal ions, NADP(H) and substrate, or
the inhibitor fosmidomycin. The NADPH binding site is
blocked by the C terminus of a neighboring molecule in the
crystal as found previously for an orthorhombic crystal form
(27). The active site is well accessible in our crystals, and
soaking with either Mn2 or Mn2 and fosmidomycin resulted
in the corresponding electron densities (Fig. 3). Mn2 is bound
to a cluster of the carbonic acids, Asp-150, Glu-152, and Glu-
231, as suggested previously (27). All residues form monoden-
tate ligands, and a regular octahedral coordination sphere is
completed by three water molecules. Upon the addition of fos-
FIG. 3. Simulated annealing Fo  Fc omit map of bound manganese and fosmidomycin at 2.5 Å resolution for both asymmetric
monomers. The contour level is 3.5 .
TABLE I
Data collection and refinement statistics
Category APO MN MNFOS
Data collection
Space group P2(1) Cell constants (a, b, c in Å/ in °) 90.4, 53.4, 107.5/92.9 91.4, 52.3, 108.3/92.5 90.8, 52.3, 107.6/92.1
Limiting resolution (Å) (last shell) 2.6 (2.60–2.70) 2.5 (2.50–2.59) 2.5 (2.50–2.59)
Reflections 31,997 35,378 34,930
Rmerge
a (overall/last shell) 6.2 (40.5) 7.2 (35.6) 8.3 (41.7)
Redundancy 3.5 3.3 3.4
Completeness (%) (overall/last shell) 98.2 (98.4) 98.8 (99.7) 98.8 (98.5)
Refinement
Resolution range (Å) 20–2.6 25–2.5 20–2.5
Reflections (working set) 29,882 (93.5%) 33,597 (93.8%) 33,163 (93.9%)
Reflections (test set) 1,557 (4.9%) 1,750 (4.9%) 1,725 (4.9%)
Rcryst(%)
b 24.4 21.6 25.5
Rfree(%)
c 29.8 28.7 33.0
Non hydrogen protein atoms 5,912 5,912 6,048
Solvent molecules 316 197 143
B-factor (Å2)
Protein 58.0 61.8 69.3
Solvent 55.8 51.7 48.5
Manganese 49.6 64.7
Fos 77.7
Root mean square deviation
Bond length [Å] 0.0105 0.0098 0.0108
Bond angle [°] 1.41 1.60 1.76
a Rmerge  hkl [i Ii  I)/iI].
b Rcryst  hkl Fobs  kFcalc/hkl Fobs for hkl  working set.
c Rfree  hkl Fobs  kFcalc/hkl Fobs for hkl  test set.
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midomycin, two water molecules are replaced by its (N-formyl-
N-hydroxy)amino head group. The geometry of the latter was
modeled similar to that observed for the inhibitor 2-((formyl-
(hydroxy)amino)methyl)-4-methylpentanoic acid complexed to
zinc in the matrix metalloproteinase MMP9 (37). The N-formyl
oxygen is found in the trans position to Glu-231, whereas the
N-hydroxyl oxygen is located trans to Asp-150 (Fig. 4). The
phosphonate moiety is anchored by numerous hydrogen bonds
to Ser-186, Ser-222, Asn-227, and Lys-228. The conformation of
the connecting linker that consists of three methylene groups
appears clearly defined by electron density. Hydrophobic con-
tacts of the latter do not seem to contribute to the high affinity
of the inhibitor, as none is present with the rigid part of the
binding site or apparently formed with the partially ordered
catalytic loop. Trp-212 from the flexible catalytic loop is in
direct vicinity to the bound inhibitor, although not well or-
dered. Replacement of His-257 by glutamine was found to have
a drastic effect on the enzyme activity (38). The kcat/Km de-
creased 27,000-fold, and the Km value for NADPH increased by
approximately one order of magnitude, although it is quite far
away from the NADPH binding site. The mutation of His-153
that is actually closer to the NADPH binding site does not have
a comparable effect. This observation may be explained by an
interaction between the His-257 site and the nicotinamide moi-
ety that is mediated by the catalytic loop. It appears likely that
His-257 and Trp-212 form a stacking interaction supported by
FIG. 5. Modeled binding modes of the substrate and the aldehyde intermediate. a, 1-D-deoxyxylulose 5-phosphate (in green) can be
excellently superimposed onto fosmidomycin (in black). b, during the reaction, C-4 migrates to C-2. The nicotinamide moiety of NADPH was
modeled according to Ref. 28 with only a slight adjustment, leaving its phosphate position unaltered. In this coordination, the stereochemistry of
the hydride transfer to C-1 (former C-3 of the substrate) is compatible with the experimental data (compare Fig. 1b).
FIG. 4. Active site geometry. The di-
valent cation (Mn2) is bound to Asp-150,
Glu-152, and Glu-231, which serve as mo-
nodentate ligands. The (N-formyl-N-hy-
droxy)amino head group of fosmidomycin
(yellow ball-and-stick model) binds to
Mn2; its phosphonate moiety is anchored
by a H-bond network including Ser-186,
Ser-222, Asn-227, and Lys-228. The cata-
lytic loop (magenta) shows only weak elec-
tron density, which indicates an interac-
tion of Trp-212 with a hydrophobic patch
formed by His-257, Pro-274, and Met-276.
A pronounced hydrophilic cavity behind
fosmidomycin harbors Ser-151 and
Ser-254.
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Pro-274 in the presence of NADPH that is a prerequisite for
completely ordering the active site architecture.
Replacement of the formyl-hydrogen of fosmidomycin by a
methyl group yields the inhibitor FR-900098 (Fig. 1c, 10) (39)
with increased affinity (6). This methyl group is predicted to
contact the side chain of Trp-212 of the catalytic loop. A corre-
sponding methyl group is present in the substrate 1-deoxyxy-
lulose 5-phosphate, which supports the view that fosmidomycin
actually binds substrate-like and does not represent an ana-
logue of the proposed intermediate 2-C-methyl-erythrose
4-phosphate as postulated previously (27). The present model
immediately reveals potential interaction sites for specific in-
hibitors. The pronounced cavity behind the bound fosmidomy-
cin (Fig. 4) can be utilized for stacking interactions with His-
257. It should be noted that this cavity is mainly formed by two
sequence stretches, His-251 to Ser-258 (His-Pro-Gln-Ser-Leu-
Ile-His-Ser) and Pro274 to Arg-277 (Pro-Asp-Met-Arg), which
represent highly conserved residues in all available IspC se-
quences. It additionally harbors the His-251 three water mol-
ecules that may be replaced by hydrophilic groups. These are
found next to the carbonyl of His-251 and Ile-256, respectively.
Substitution at the 3 and 5 positions of the five-member skel-
eton appear especially suited to include these contacts.
Active Site Geometry and Enzyme Mechanism—Previous
structural studies on IspC revealed its principal domain orga-
nization (27) and the binding site for NADPH and indicated a
phosphate binding site (28). However, no information was
available on the binding site for divalent metal ions and the
substrate DXP, and no model could be derived for the course of
the reaction. The complex of IspC with Mn2 and fosmidomycin
now provides a model for the binding mode of the substrate.
DXP can be fitted nicely onto fosmidomycin (Fig. 5a). During
the reaction, the C-4 atom migrates to the C-2 carbon atom,
which is partially positively charged because of the polarizing
effect of the divalent metal ion. The C-3 hydroxyl is likewise
fixed by coordination to the metal ion. This first step is similar
to that catalyzed by acetohydroxy acid isomeroreductase,
which is involved in the biosynthesis of branched amino acids.
There, a carbonyl group is also further polarized by a Mg2 ion,
inducing a partial positive charge on the carbon atom (reviewed
in Ref. 40).
From stereochemical considerations is has been deduced that
the migrating group and the reducing cofactors are located on
opposite faces of the planes defined by the metal coordinated
-hydroxycarbonyl substructures (20). A binding mode of the
intermediate 2-C-methyl-erythrose 4-phosphate (8) in an ex-
tended conformation similar to fosmidomycin (9) is not compat-
ible with the stereochemistry of the reduction reaction, as it
would result in a hydride transfer to the Hsi position at C-1 of
the product from Hsi at C-4 of the cofactor and not to Hre as
observed (20–22). Therefore, we postulate that the putative
intermediate does not relax to an extended substrate-like con-
formation. It is reasonable to assume that the phosphate group
of the substrate remains essentially anchored in the phosphate
binding site during the reaction. Notably, 1-D-deoxyxylulose
does not act as a substrate for the enzyme (19). Therefore,
migration of the C-4 atom to the C-2 carbonyl during isomer-
ization will likely require a movement of C-2 toward the phos-
phate binding site. If it is additionally assumed that the oxygen
ligands remain bound to the divalent metal ion throughout the
reaction, a binding mode of the intermediate as illustrated in
Fig. 5b can be modeled.
The NADP-bound IspC model (28) can be superimposed onto
our fosmidomycin complex with only minor differences. This
allows modeling of NADPH in a substrate complex (Figs. 2 and
5b). It should be particularly noted that the resulting geometry
of the reaction intermediate not only brings the aldehyde group
of the intermediate in close proximity ( 3.2 Å) to the C-4
position of the NADPH nicotinamide moiety, but also results in
the observed hydride transfer to the Hre position at C-1 of the
product. The methyl group at C-2 is predicted to remain ex-
posed to Trp-212 of the catalytic loop. It has been shown that
this methyl group is essential for the affinity of the aldehyde
intermediate to the enzyme as D-erythrose 4-phosphate binds
significantly weaker (19). The hydride transfer may occur very
rapidly, perhaps concomitantly with the isomerization reac-
tion, which is compatible with the fact that the putative inter-
mediate cannot be isolated or trapped. The presence of NADPH
during the reaction is assured by an ordered sequential binding
starting with NADPH as demonstrated by kinetic studies (23).
The finding that the reversible isomerization step requires the
presence of NADP/NADPH indicates that it helps to define
the precise active site geometry, presumably by interacting
with the flexible active site loop. The strictly conserved resi-
dues Trp-212 and Met-214 represent ideal candidates for a
stacking interaction or a hydrophobic contact with the nicotin-
amide moiety of NADPH. We therefore conclude that the cat-
alytic loop and the nicotinamide moiety of NADPH are simul-
taneously required for their correct positioning at the active
site. A recent NMR study demonstrated the proximity of a
methionine and an isoleucine residue to the nicotinamide ring
portion of NADPH (41). Potential candidates at the active site
are Met-214 or Met-276 and Ile-13 or Ile-218, respectively,
which all represent almost strictly conserved residues.
In summary, we could demonstrate the binding mode of
fosmidomycin to IspC, which must, for stereochemical reasons,
be different from that of the aldehyde intermediate, 2-C-meth-
yl-erythrose 4-phosphate, as proposed previously. The detailed
knowledge of the interaction mode of fosmidomycin as a prom-
ising drug against malaria and lead compound may contribute
to the development of more potent inhibitors of this key
enzyme.
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